Brought to you by 
Juno buys Stage Cell Therapeutics for €52mm plus €135mm in earn-outs
29 Sep 2020
Executive Summary
Juno Therapeutics Inc. paid €52mm ($59mm) in cash and issued 486k of its shares (valued at €20mm) to acquire the 95% of German biotech Stage Cell Therapeutics GMBH that it didn’t already down. Stage Cell will operate as a wholly owned subsidiary, and will be renamed Juno Therapeutics GMBH.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Includes Contract
- Includes Earnout
- Intra-Biotech Deal
- Partial Acquisition
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com